

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
N=:		268	268	318	318
AGE AT ENTRY:	n	268	268	318	318
	mean (std)	68.5 (9.1)	66.2 (8.9)	64.2 (9.0)	62.2 (8.7)
	minimum	0.0	0.0	40.0	39.0
	25th-percentile	63.5	60.0	57.0	56.0
	median	69.0	66.0	64.0	61.0
	75th-percentile	74.0	73.0	72.0	69.0
	maximum	91.0	86.0	84.0	84.0
RACE:	white	253 (94.4 %)	254 (94.8 %)	312 (98.1 %)	308 (96.9 %)
	black	3 (1.1 %)	2 (0.7 %)	1 (0.3 %)	1 (0.3 %)
	hispanic	10 (3.7 %)	10 (3.7 %)	1 (0.3 %)	3 (0.9 %)
	american indian/alas	0 (0.0 %)	0 (0.0 %)	1 (0.3 %)	0 (0.0 %)
	other	1 (0.4 %)	1 (0.4 %)	0 (0.0 %)	1 (0.3 %)
	missing	1 (0.4 %)	1 (0.4 %)	3 (0.9 %)	5 (1.6 %)
DIABETES(TYPE 1 & TYPE 2):	no	220 (82.1 %)	228 (85.1 %)	275 (86.5 %)	292 (91.8 %)
	yes	48 (17.9 %)	40 (14.9 %)	43 (13.5 %)	26 (8.2 %)
TYPE 1 or TYPE 2 DIABETES(DIAB.ONLY):	Type 1 Diabetes	6 (12.5 %)	5 (12.5 %)	9 (20.9 %)	7 (26.9 %)
	Type 2 Diabetes	38 (79.2 %)	35 (87.5 %)	33 (76.7 %)	19 (73.1 %)
	Unknown Type Diabete	4 (8.3 %)	0 (0.0 %)	1 (2.3 %)	0 (0.0 %)
PANCREAS TRANSPLANT:	no	197 (73.5 %)	192 (71.6 %)	184 (57.9 %)	181 (56.9 %)
	missing	71 (26.5 %)	76 (28.4 %)	134 (42.1 %)	137 (43.1 %)

The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.

*Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
DURATION of DIAB(yrs)(DIAB ONLY):	n	45	40	42	26
	mean (std)	16.5 (14.4)	15.9 (15.4)	18.5 (14.8)	18.5 (14.0)
	minimum	0.0	0.0	0.0	2.0
	25th-percentile	3.0	3.0	5.0	8.0
	median	12.0	10.5	14.5	15.5
	75th-percentile	24.0	25.0	30.0	30.0
	maximum	53.0	53.0	55.0	57.0
TAKING INSULIN(NON-PANCR TRANS.):	no	28 (58.3 %)	22 (55.0 %)	21 (48.8 %)	11 (42.3 %)
	yes	20 (41.7 %)	18 (45.0 %)	21 (48.8 %)	15 (57.7 %)
	missing	0 (0.0 %)	0 (0.0 %)	1 (2.3 %)	0 (0.0 %)
INSUL. REGIMEN(NON-PANCR TRANS.):	<2 Shots	5 (25.0 %)	2 (11.1 %)	3 (14.3 %)	2 (13.3 %)
	MDI	13 (65.0 %)	14 (77.8 %)	12 (57.1 %)	9 (60.0 %)
	pump	1 (5.0 %)	2 (11.1 %)	5 (23.8 %)	3 (20.0 %)
	missing	1 (5.0 %)	0 (0.0 %)	1 (4.8 %)	1 (6.7 %)
INSUL DOSAGE(units/kg/day):	n	21	18	23	16
	mean (std)	0.6 (0.4)	0.7 (0.4)	0.5 (0.3)	0.4 (0.2)
	minimum	0.0	0.0	0.0	0.0
	25th-percentile	0.4	0.5	0.2	0.3
	median	0.5	0.6	0.5	0.4
	75th-percentile	0.7	0.7	0.7	0.6
	maximum	1.6	1.8	1.0	1.0

*The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.
Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
FOCAL LASER TREATMENT:	no	265 (98.9 %)	267 (99.6 %)	316 (99.4 %)	317 (99.7 %)
	yes	0 (0.0 %)	1 (0.4 %)	2 (0.6 %)	0 (0.0 %)
	unknown	2 (0.7 %)	0 (0.0 %)	0 (0.0 %)	0 (0.0 %)
	missing	1 (0.4 %)	0 (0.0 %)	0 (0.0 %)	1 (0.3 %)
PAN-RETINAL LASER TREATMENT:	no	256 (95.5 %)	262 (97.8 %)	308 (96.9 %)	316 (99.4 %)
	yes	10 (3.7 %)	6 (2.2 %)	10 (3.1 %)	1 (0.3 %)
	unknown	2 (0.7 %)	0 (0.0 %)	0 (0.0 %)	0 (0.0 %)
	missing	0 (0.0 %)	0 (0.0 %)	0 (0.0 %)	1 (0.3 %)
ESRD:	no	268 (100.0 %)	267 (99.6 %)	316 (99.4 %)	318 (100.0 %)
	yes	0 (0.0 %)	1 (0.4 %)	2 (0.6 %)	0 (0.0 %)
ACR1(ug/mg)(NON_ESRD ONLY):	n	259	252	308	309
	mean (std)	124.1 (563.5)	62.1 (425.1)	35.2 (187.3)	18.6 (130.4)
	minimum	0.5	0.8	0.5	0.5
	25th-percentile	4.9	5.9	4.1	4.5
	median	8.5	9.8	5.7	6.5
	75th-percentile	24.3	17.5	11.8	10.0
	maximum	5550.2	6339.4	2900.0	2274.0
CARDIOVASCULAR COMPLICATION:	no	96 (35.8 %)	108 (40.3 %)	153 (48.1 %)	193 (60.7 %)
	yes	172 (64.2 %)	160 (59.7 %)	165 (51.9 %)	125 (39.3 %)
HYPERTENSIVE:	no	128 (47.8 %)	126 (47.0 %)	179 (56.3 %)	210 (66.0 %)
	yes	139 (51.9 %)	142 (53.0 %)	139 (43.7 %)	108 (34.0 %)
	unknown	1 (0.4 %)	0 (0.0 %)	0 (0.0 %)	0 (0.0 %)

The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.

*Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
NEUROPATHY*:	no	16 (6.0 %)	10 (3.7 %)	32 (10.1 %)	30 (9.4 %)
	yes	5 (1.9 %)	5 (1.9 %)	4 (1.3 %)	2 (0.6 %)
	unknown	0 (0.0 %)	0 (0.0 %)	1 (0.3 %)	1 (0.3 %)
	missing	247 (92.2 %)	253 (94.4 %)	281 (88.4 %)	285 (89.6 %)
PERIPHERAL VASCULAR DISEASE*:	no	84 (31.3 %)	85 (31.7 %)	165 (51.9 %)	166 (52.2 %)
	yes	7 (2.6 %)	5 (1.9 %)	4 (1.3 %)	3 (0.9 %)
	missing	177 (66.0 %)	178 (66.4 %)	149 (46.9 %)	149 (46.9 %)
AUTO-IMMUNE DISEASE:	No	249 (92.9 %)	232 (86.6 %)	275 (86.5 %)	261 (82.1 %)
	Yes (with 1 disease)	16 (6.0 %)	32 (11.9 %)	34 (10.7 %)	45 (14.2 %)
	Yes (with >1 disease)	3 (1.1 %)	4 (1.5 %)	9 (2.8 %)	12 (3.8 %)
CURRENT SMOKING*:	no	84 (31.3 %)	78 (29.1 %)	149 (46.9 %)	162 (50.9 %)
	yes	7 (2.6 %)	12 (4.5 %)	18 (5.7 %)	6 (1.9 %)
	missing	177 (66.0 %)	178 (66.4 %)	151 (47.5 %)	150 (47.2 %)
EVER SMOKER*:	no	22 (8.2 %)	51 (19.0 %)	76 (23.9 %)	101 (31.8 %)
	yes	69 (25.7 %)	40 (14.9 %)	93 (29.2 %)	68 (21.4 %)
	missing	177 (66.0 %)	177 (66.0 %)	149 (46.9 %)	149 (46.9 %)

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
SYSTOLIC BP (mm Hg):	n	261	261	301	299
	mean (std)	131.8 (15.8)	132.5 (16.7)	130.0 (14.1)	126.0 (15.0)
	minimum	97.0	88.0	93.0	90.0
	25th-percentile	120.0	121.0	120.0	116.5

*The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.
Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE		CONTROL	
CHARACTERISTIC	STATISTICS/ CATEGORIES	FATHER	MOTHER	FATHER	MOTHER
	median	130.0	131.0	130.0	125.0
	75th-percentile	140.0	143.0	138.0	134.0
	maximum	196.0	199.0	182.0	170.0
DIASTOLIC BP (mm Hg):	n	261	261	301	301
	mean (std)	75.5 (9.8)	74.9 (9.5)	76.6 (8.4)	74.8 (9.4)
	minimum	54.0	45.0	53.5	49.5
	25th-percentile	69.0	69.0	70.5	69.0
	median	76.0	76.0	77.0	75.0
	75th-percentile	81.0	80.0	82.0	80.0
	maximum	107.0	103.0	110.0	109.0
BODY MASS INDEX (kg/m ²):	n	262	262	298	298
	mean (std)	28.7 (4.7)	27.9 (5.5)	28.4 (4.3)	27.5 (5.0)
	minimum	15.5	18.0	16.5	17.9
	25th-percentile	25.3	24.1	25.5	23.4
	median	28.2	27.0	27.7	27.0
	75th-percentile	31.1	30.9	30.4	30.0
	maximum	44.5	48.6	49.9	47.8

*The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.
Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
NATURAL WAIST CIRCUM.(cm):*	n	84	85	153	152
	mean (std)	102.7 (12.6)	92.5 (15.1)	102.9 (11.7)	89.2 (13.9)
	minimum	77.5	65.8	67.6	32.2
	25th-percentile	93.7	83.0	95.2	79.4
	median	101.6	89.0	101.6	89.9
	75th-percentile	111.4	100.0	109.0	98.6
	maximum	134.9	138.3	144.9	123.2
GFR(Cockcroft-Gault)(ml/min):	n	216	216	284	286
	mean (std)	81.6 (29.0)	74.0 (39.9)	88.5 (25.2)	77.9 (24.3)
	minimum	25.4	12.1	29.1	19.6
	25th-percentile	61.7	54.2	70.8	63.6
	median	79.1	69.9	85.1	74.6
	75th-percentile	97.4	86.6	103.5	91.1
	maximum	247.4	540.1	190.0	176.9
HBA1C (%):	n	259	257	308	309
	mean (std)	5.9 (1.2)	5.7 (1.1)	5.7 (1.0)	5.5 (0.6)
	minimum	4.3	3.9	4.4	3.8
	25th-percentile	5.3	5.2	5.2	5.2
	median	5.6	5.5	5.4	5.4
	75th-percentile	6.0	6.0	5.8	5.7
	maximum	13.0	10.7	12.4	8.9

*The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.
Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE		CONTROL	
CHARACTERISTIC	STATISTICS/ CATEGORIES	FATHER	MOTHER	FATHER	MOTHER
TOTAL CHOLESTEROL (mg/dL):	n	217	217	295	296
	mean (std)	189.6 (37.1)	211.1 (39.5)	187.8 (34.8)	211.5 (35.8)
	minimum	113.0	111.0	107.0	121.0
	25th-percentile	164.0	182.0	166.0	187.0
	median	186.0	207.0	185.0	208.0
	75th-percentile	215.0	237.0	207.0	233.5
	maximum	299.0	335.0	314.0	345.0
HDL (mg/dL):	n	218	218	296	298
	mean (std)	45.3 (14.5)	55.9 (16.8)	45.4 (14.0)	56.8 (14.2)
	minimum	13.0	29.0	18.0	22.0
	25th-percentile	36.0	43.0	36.0	46.0
	median	42.0	53.5	44.0	55.5
	75th-percentile	51.0	64.0	52.0	66.0
	maximum	102.0	112.0	112.0	102.0
SERUM CREATININE (mg/dL):	n	204	216	292	295
	mean (std)	1.1 (0.3)	0.9 (0.2)	1.1 (0.2)	0.9 (0.2)
	minimum	0.5	0.1	0.8	0.5
	25th-percentile	1.0	0.8	1.0	0.8
	median	1.1	0.9	1.1	0.9
	75th-percentile	1.3	1.1	1.2	1.0
	maximum	3.2	1.8	2.2	1.7

*The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.
Characteristic ended with * are data collected by GWU only.*

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF PARENTS OF ELIGIBLE TRIO PROBANDS
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE		CONTROL	
		FATHER	MOTHER	FATHER	MOTHER
SERUM CYSTATIN (mg/L):	n	211	213	291	291
	mean (std)	1.2 (0.4)	1.1 (0.5)	1.0 (0.3)	1.0 (0.3)
	minimum	0.7	0.7	0.5	0.6
	25th-percentile	0.9	0.9	0.9	0.8
	median	1.1	1.0	1.0	1.0
	75th-percentile	1.3	1.2	1.1	1.1
	maximum	2.6	6.7	2.7	2.4
ABNORMAL SERUM CREATININE:	no	240 (89.6 %)	248 (92.5 %)	303 (95.3 %)	308 (96.9 %)
	yes	28 (10.4 %)	20 (7.5 %)	15 (4.7 %)	10 (3.1 %)
TAKING LIPID LOWERING MEDICATION:	no	173 (64.6 %)	194 (72.4 %)	195 (61.3 %)	237 (74.5 %)
	yes	95 (35.4 %)	72 (26.9 %)	115 (36.2 %)	77 (24.2 %)
	missing	0 (0.0 %)	2 (0.7 %)	8 (2.5 %)	4 (1.3 %)
TAKING ACE INHIBITORS:	no	180 (67.2 %)	195 (72.8 %)	219 (68.9 %)	265 (83.3 %)
	yes	83 (31.0 %)	66 (24.6 %)	79 (24.8 %)	47 (14.8 %)
	missing	5 (1.9 %)	7 (2.6 %)	20 (6.3 %)	6 (1.9 %)
TAKING ANTI-HYPERTENSIVE DRUGS:	no	131 (48.9 %)	152 (56.7 %)	175 (55.0 %)	212 (66.7 %)
	yes	132 (49.3 %)	110 (41.0 %)	120 (37.7 %)	95 (29.9 %)
	missing	5 (1.9 %)	6 (2.2 %)	23 (7.2 %)	11 (3.5 %)

*The number of TRIO PARENTS in this report might be lower than the number of TRIO PROBANDS in all proband report, because some families might have multiple siblings enrolled in the study.
Characteristic ended with * are data collected by GWU only.*